Peptides

Therapeutic Peptides: What the Science Says So Far

What Are Therapeutic Peptides?

Peptides are short chains of amino acids - the same building blocks that make up the proteins in your body. Some peptides occur naturally in your tissues and play important roles in healing, inflammation, and cell repair. In recent years, synthetic versions of these peptides have become widely marketed for injury recovery, anti-aging, performance enhancement, and general wellness.

This page is intended to help you understand what the current science does and does not tell us about these compounds. While many patients are already using peptides, it is important to know that the vast majority of the evidence comes from animal studies, and rigorous human clinical trials are largely absent. For that reason, this practice does not currently recommend peptide therapy as a standard treatment. However, because so many patients are using these products - often without medical guidance - the information below is provided so that those who choose to use peptides can do so as safely and as informed as possible.

The Most Commonly Discussed Peptides

BPC-157 (Body Protection Compound 157)

BPC-157 is a 15-amino-acid peptide originally isolated from human gastric (stomach) juice. In animal studies - primarily in rats - BPC-157 has shown consistently positive effects on healing of tendons, ligaments, muscles, bones, skin wounds, and gastrointestinal ulcers. It appears to work by promoting new blood vessel formation (angiogenesis), modulating the nitric oxide system, and upregulating growth factor expression.

In preclinical toxicity studies, no lethal dose has been identified (meaning researchers could not find a dose high enough to cause death in animals), and few side effects have been reported in animal models.

However, human data are extremely limited. Only a single small case series has reported improvements in knee pain after intra-articular injection of BPC-157, and that study had significant methodological flaws and no control group. BPC-157 has not been approved by the FDA for any medical use, and optimal dosing, frequency, and duration of treatment in humans remain unknown.

In animal studies, BPC-157 has been administered via injection (into the abdomen, into muscle, or directly into tissue), orally (in drinking water or by mouth), and topically (as a cream). Doses used in rat studies have typically ranged from 10 micrograms per kilogram of body weight, given once daily. Pharmacokinetic studies in rats and dogs show that the peptide is rapidly broken down, with a half-life of less than 30 minutes after intravenous injection.

Thymosin Beta-4 (Tβ4) and TB-500

Thymosin beta-4 is a naturally occurring 43-amino-acid peptide found in nearly all human cells and body fluids. It is released by platelets at sites of injury and plays a role in cell migration, blood vessel formation, reducing inflammation, and promoting stem cell activity. TB-500 is a synthetic fragment of thymosin beta-4 that contains its key active region.

In animal models, thymosin beta-4 has accelerated healing of skin wounds (including in diabetic and aged mice), corneal injuries, and cardiac tissue after heart attacks. Two phase 2 clinical trials in humans with chronic skin ulcers (stasis ulcers and pressure ulcers) showed that thymosin beta-4 accelerated healing by nearly a month in patients who responded.

Despite these promising early results, there are no large-scale human trials confirming safety or effectiveness for musculoskeletal injuries. Both Tβ4 and TB-500 remain banned by the World Anti-Doping Agency (WADA) for use in competitive sports.

CJC-1295 and Ipamorelin

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to have a much longer duration of action than natural GHRH. In a human study of healthy adults, a single subcutaneous injection of CJC-1295 produced dose-dependent increases in growth hormone levels (2- to 10-fold) lasting 6 or more days, and increases in IGF-1 levels lasting 9 to 11 days. The estimated half-life was approximately 6 to 8 days. No serious adverse reactions were reported in that study.

Ipamorelin is a growth hormone secretagogue (a substance that stimulates growth hormone release). It is often combined with CJC-1295 in clinical practice. In animal studies, the combination improved muscle strength in mice with steroid-induced muscle loss, but these findings have not been validated in humans.

Neither CJC-1295 nor ipamorelin is FDA-approved for any indication.

GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper)

GHK-Cu is a naturally occurring copper-binding peptide found in human plasma, saliva, and urine. In laboratory and animal studies, it has shown wound-healing, anti-inflammatory, and antioxidant properties. It has been used in some cosmetic and skincare products. However, no clinical data support its use for musculoskeletal conditions or internal medical use.

Why This Practice Cannot Yet Recommend Peptide Therapy

The preclinical (animal) data on many of these peptides is genuinely interesting and, in some cases, remarkably consistent. However, there are critical gaps that prevent a responsible medical recommendation at this time:

• Almost all evidence comes from animal studies, primarily in rats and mice. Results in animals frequently do not translate to humans.
• There are no FDA-approved indications for BPC-157, TB-500, CJC-1295/ipamorelin, or GHK-Cu for healing, performance, or anti-aging purposes.
• Optimal dosing, treatment duration, frequency, and route of administration in humans have not been established through clinical trials.
• Long-term safety data in humans do not exist for most of these compounds.
• Much of the preclinical research on BPC-157 has been conducted by a small number of research groups, which limits independent verification of results.

Serious Concerns About Safety, Supply, and Administration

Even for patients who choose to use peptides despite the limited evidence, there are important safety concerns that go beyond whether the peptides themselves “work”:

Product Quality and Contamination

Most peptides available to consumers are obtained from compounding pharmacies or online suppliers that operate outside of standard FDA oversight. Compounded products do not undergo FDA review for safety, quality, or effectiveness. A systematic analysis of falsified peptide products purchased from online sources found:

• Purity levels as low as 5% to 75% (meaning the product may contain far less active ingredient than labeled - or far more)
• Contamination with toxic heavy metals, including arsenic at concentrations up to 10 times the accepted safety limit for injectable drugs, and lead
• High levels of peptide-related impurities and unknown contaminants

A separate analysis of compounded injectable products reported through the FDA’s adverse event system found significantly higher rates of preparation errors, contamination, and manufacturing issues compared to FDA-approved products, as well as higher rates of hospitalization.

Risks of Self-Injection

Many peptide protocols involve subcutaneous or intramuscular self-injection. Without proper training and sterile technique, this carries risks of:

• Infection at the injection site (including abscess formation)
• Contamination of multi-dose vials with bacteria
• Dosing errors due to improper reconstitution or measurement
• Allergic or adverse reactions without medical supervision nearby

How to Reduce Risk If You Choose to Use Peptides

If you decide to use peptide therapy despite the limitations described above, the following steps may help reduce - but cannot eliminate - risk:

• Only obtain peptides from a pharmacy that is either registered with the FDA as a 503B outsourcing facility or licensed by your state board of pharmacy as a 503A compounding pharmacy. You can verify 503B registration on the FDA website.
• Never purchase peptides from unverified online sources, overseas suppliers, or websites that do not require a prescription.
• Ensure the product has a clear label listing the exact contents, dosage, lot number, and expiration date.
• Inspect the product before use - it should be clear and free of particles.
• Use proper sterile technique for reconstitution and injection. Use alcohol swabs on vial tops and injection sites, use a new sterile needle and syringe for every injection, and never share vials or needles.
• Store peptides according to the label instructions (most require refrigeration after reconstitution).
• Report any adverse effects to your healthcare provider and to the FDA’s MedWatch system.

Published Dosing Information

The following dosing information has been reported in the published scientific literature. These are not recommendations from this practice. They are provided solely for informational purposes because many patients are already using these compounds and may benefit from understanding what has been studied.

BPC-157: Animal studies have typically used doses in the range of 10 mcg/kg body weight per day, administered by injection or orally. Pharmacokinetic studies show rapid metabolism with a half-life under 30 minutes. No validated human dosing protocol exists.

Thymosin Beta-4 / TB-500: In human clinical trials for skin ulcers, thymosin beta-4 was applied topically. Dosing for injectable TB-500 in humans has not been established in clinical trials.

CJC-1295: In a published human study, single subcutaneous doses of 30 to 60 mcg/kg were well tolerated and produced sustained increases in growth hormone and IGF-1 levels. Multiple doses were given weekly or biweekly.

Ipamorelin: Human dosing data from clinical trials are limited. It is often combined with CJC-1295 in practice, but no validated combination protocol has been published.

GHK-Cu: Used topically in some skincare formulations. No established injectable dosing protocol exists for medical use.

The Bottom Line

Therapeutic peptides represent an area of active scientific interest with genuinely promising preclinical data. However, the gap between animal research and proven human therapy remains wide. Until rigorous clinical trials establish safety, efficacy, and proper dosing in humans, these products cannot be considered evidence-based treatments.

This practice takes patient autonomy seriously. If you are using or considering peptides, please discuss this openly with your provider so that appropriate monitoring can be arranged and risks can be minimized. The goal is not to judge your choices, but to help you make them as safely as possible.

With that in mind, patients have asked me about reputable suppliers and so I have provided the link below for one such supplier. For additional information please go to: https://peptiderestore.com/